Recent Press Releasess
09.08.2024
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
09.06.2024
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
08.28.2024
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
08.26.2024
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress